UroGen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results

UroGen Pharma (NASDAQ:URGN) posted its quarterly earnings data on Wednesday. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29, RTT News reports. The business had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter last year, the business earned ($0.68) EPS.

UroGen Pharma Stock Down 1.1 %

Shares of URGN traded down $0.14 during trading on Thursday, reaching $12.10. The company’s stock had a trading volume of 303,960 shares, compared to its average volume of 502,973. The company has a market cap of $283.75 million, a price-to-earnings ratio of -3.70 and a beta of 1.12. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. The company has a fifty day moving average of $12.82 and a two-hundred day moving average of $14.20. UroGen Pharma has a twelve month low of $10.60 and a twelve month high of $20.70.

Analysts Set New Price Targets

URGN has been the subject of a number of research analyst reports. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Guggenheim assumed coverage on UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.